

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Akio Nakamura

Application No.: National Phase of
PCT/JP2005/001492

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: GLYCOSIDE PRODRUG OF 5-
AMINOSALICYLIC ACID

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

A summary/abstract translation of the non-English language documents is enclosed.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Other information being provided for the examiner's consideration follows:

An International Search Report, mailed April 19, 2005, which issued during the prosecution of International Application No. PCT/JP2005/001492 which corresponds to the present application.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: August 3, 2006

Respectfully submitted,

By 

Dianna Goldenson

Registration No.: 52,949

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Page 4
Reg. No: 52,970

Substitute for form 1449A/B/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;">(Use as many sheets as necessary)</p>		Complete If Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Filing Date</td> <td>Concurrently Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Akio Nakamura</td> </tr> <tr> <td>Art Unit</td> <td>N/A</td> </tr> <tr> <td>Examiner Name</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>20855/0205125-USO</td> </tr> </table>		Application Number	Not Yet Assigned	Filing Date	Concurrently Herewith	First Named Inventor	Akio Nakamura	Art Unit	N/A	Examiner Name	Not Yet Assigned	Attorney Docket Number	20855/0205125-USO
Application Number	Not Yet Assigned														
Filing Date	Concurrently Herewith														
First Named Inventor	Akio Nakamura														
Art Unit	N/A														
Examiner Name	Not Yet Assigned														
Attorney Docket Number	20855/0205125-USO														
Sheet	1	of	2												

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number/Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,637,229	06-06-1989	Rokos et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ /Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
	BA	WO-84/04041-A1	10-25-1984	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA		
	BB	JP-60-501105-A	07-18-1985	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	Corresponds to Citation No. BA	✓
	BC	JP-60-68061-A	04-19-1985	HENNING BERLIN GMBH CHEMIE- UND PHARMAWERK	Corresponds to Citation No. AA	✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supported under 37 CFR 1.56(a)(2)(ii) because that application was filed after June 30, 2003 or is available in the prior art. † Applicant's unique citation designation number (optional). ‡ See Rende Codes of USPTO Patent Documents at www.uspto.gov/patents/USPTO/PatentDocuments/USPTO/PatentDocuments.htm. § For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¶ Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST.15 if possible. ** Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	†	‡	§	¶
	CA	KOICHI NAKAMARU, et al., Effect of mesalazine, an agent for the treatment of idiopathic inflammatory bowel disease, on reactive oxygen metabolites and LTB ₄ formation, <i>Folia Pharmacol. Jpn.</i> , 104, pp. 447-457, 1994	✓			
	CB	KOICHI NAKAMARU, et al., Effect of mesalazine microgranules on experimental colitis, <i>Folia Pharmacol. Jpn.</i> , 104, pp. 303-311, 1994	✓			
	CC	M. C. M. RIJK, et al., Disposition of 5-Aminosalicylic Acid by 5-Aminosalicylic Acid-Delivering Compounds, <i>Scandinavian Journal of Gastroenterology</i> , 23, pp. 107-112, 1988				
	CD	DAVID R. FRIEND, Colon-specific drug delivery, <i>Advanced Drug Delivery Reviews</i> , 7, pp. 149-199, 1991				
	CE	HARUO HIGAKI, et al., Clinical Studies of Oral Controlled-Release Mesalazine, N-5ASA, <i>Japanese Pharmacology & Therapeutics</i> , Vol. 22, Suppl. 10, 1994	✓			
	CF	ISTVAN CSISO, et al., 5-Amino-szalicilsav- es glukozidjai, <i>Magyar Kemiai Folyoirat</i> , 97(4), pp. 143-148, 1991	✓			
	CG	FERENC SZTARICSZAI, et al., Antulcer Effect of the N- and O-β-D-Glucopyranosides of 5-Aminosalicylic Acid, <i>Archiv der Pharmazie An International Journal Pharmaceutical and Medicinal Chemistry</i> , 332(9), pp. 321-326, 1999				
	CH	MICHIYUKA GOTO, Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs, <i>Journal of Pharmacy and Pharmacology</i> , 53, pp. 1711-1720, 2001				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supported under 37 CFR 1.56(a)(2)(ii) because that application was filed after June 30, 2003 or is available in the prior art. † Applicant's unique citation designation number (optional). ‡ See Rende Codes of USPTO Patent Documents at www.uspto.gov/patents/USPTO/PatentDocuments/USPTO/PatentDocuments.htm. § For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¶ Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST.15 if possible. ** Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------